Cargando…

Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer

BACKGROUND: Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlo, Sebastjan, Besic, Nikola, Drmota, Eva, Kovacevic, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366730/
https://www.ncbi.nlm.nih.gov/pubmed/33675192
http://dx.doi.org/10.2478/raon-2021-0013
_version_ 1783738939663712256
author Merlo, Sebastjan
Besic, Nikola
Drmota, Eva
Kovacevic, Nina
author_facet Merlo, Sebastjan
Besic, Nikola
Drmota, Eva
Kovacevic, Nina
author_sort Merlo, Sebastjan
collection PubMed
description BACKGROUND: Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA) 125 is used as a prognostic marker and its level is elevated in more than 85% of women with advanced stages of epithelial ovarian cancer (EOC). The standard treatment is primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT), but the later approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Several studies have been conducted to find out whether preoperative CA-125 serum levels influence treatment choice, surgical resection and survival outcome. The aim of our study was to analyse experience of single institution as Cancer comprehensive center with preoperative usefulness of CA-125. PATIENTS AND METHODS: At the Institute of Oncology Ljubljana a retrospective analysis of 253 women with stage FIGO IIIC and IV ovarian cancer was conducted. Women were divided into two groups based on their primary treatment. The first group was the NACT group (215 women) and the second the PDS group (38 women). The differences in patient characteristics were compared using the Chi-square test and ANOVA and the Kaplan-Meier method was used for calculating progression-free survival (PFS) and overall survival (OS). RESULTS: The median serum CA-125 level was higher in the NACT group than in the PDS group, 972 IU/ml and 499 IU/ ml, respectively. The PFS in the NACT group was 8 months (95% CI 6.4–9.5) and 18 months (95% CI 12.5–23.4) in the PDS group. The median OS was lower in the NACT group than in the PDS group, 25 months (95% CI 20.6–29.5) and 46 months (95% CI 32.9–62.1), respectively. CONCLUSIONS: Preoperative CA-125 cut off value of 500 IU/ml is a promising threshold to predict a successful PDS.
format Online
Article
Text
id pubmed-8366730
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-83667302021-09-01 Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer Merlo, Sebastjan Besic, Nikola Drmota, Eva Kovacevic, Nina Radiol Oncol Research Article BACKGROUND: Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA) 125 is used as a prognostic marker and its level is elevated in more than 85% of women with advanced stages of epithelial ovarian cancer (EOC). The standard treatment is primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT), but the later approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Several studies have been conducted to find out whether preoperative CA-125 serum levels influence treatment choice, surgical resection and survival outcome. The aim of our study was to analyse experience of single institution as Cancer comprehensive center with preoperative usefulness of CA-125. PATIENTS AND METHODS: At the Institute of Oncology Ljubljana a retrospective analysis of 253 women with stage FIGO IIIC and IV ovarian cancer was conducted. Women were divided into two groups based on their primary treatment. The first group was the NACT group (215 women) and the second the PDS group (38 women). The differences in patient characteristics were compared using the Chi-square test and ANOVA and the Kaplan-Meier method was used for calculating progression-free survival (PFS) and overall survival (OS). RESULTS: The median serum CA-125 level was higher in the NACT group than in the PDS group, 972 IU/ml and 499 IU/ ml, respectively. The PFS in the NACT group was 8 months (95% CI 6.4–9.5) and 18 months (95% CI 12.5–23.4) in the PDS group. The median OS was lower in the NACT group than in the PDS group, 25 months (95% CI 20.6–29.5) and 46 months (95% CI 32.9–62.1), respectively. CONCLUSIONS: Preoperative CA-125 cut off value of 500 IU/ml is a promising threshold to predict a successful PDS. Sciendo 2021-08-10 /pmc/articles/PMC8366730/ /pubmed/33675192 http://dx.doi.org/10.2478/raon-2021-0013 Text en © 2021 Sebastjan Merlo, Nikola Besic, Eva Drmota, Nina Kovacevic, published by Sciendo https://creativecommons.org/licenses/by-nc-nd/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Research Article
Merlo, Sebastjan
Besic, Nikola
Drmota, Eva
Kovacevic, Nina
Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
title Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
title_full Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
title_fullStr Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
title_full_unstemmed Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
title_short Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
title_sort preoperative serum ca-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366730/
https://www.ncbi.nlm.nih.gov/pubmed/33675192
http://dx.doi.org/10.2478/raon-2021-0013
work_keys_str_mv AT merlosebastjan preoperativeserumca125levelasapredictorfortheextentofcytoreductioninpatientswithadvancedstageepithelialovariancancer
AT besicnikola preoperativeserumca125levelasapredictorfortheextentofcytoreductioninpatientswithadvancedstageepithelialovariancancer
AT drmotaeva preoperativeserumca125levelasapredictorfortheextentofcytoreductioninpatientswithadvancedstageepithelialovariancancer
AT kovacevicnina preoperativeserumca125levelasapredictorfortheextentofcytoreductioninpatientswithadvancedstageepithelialovariancancer